{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.6","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.8","value":"28.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week 35 n=41"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Body mass index was one of the measurements of clinical symptoms of CD. Body mass index=weight in kg divided by the square of the body height (in meters)","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline and week 35","title":"Body Mass Index at Week 35","type":"SECONDARY","unitOfMeasure":"kg/m2"}